Search

Search bills, members, committees and pages...

NOVARTIS, INC.

28 federal lobbying filings, 2023 to 2026.

NOVARTIS, INC. is a client on 28 federal lobbying filings, 2023 to 2026, reporting $1.5M across them. Multinational biopharmaceutical company Based in District of Columbia.

An LDA filing reports one registrant’s income from one client for everything they worked that quarter, so a total here is the sum of whole filings and never a price for one issue or one bill.


Firms

2 it has hired, by filings.

RegistrantFilingsReported
FORBES-TATE14$700K
TODD STRATEGY GROUP14$760K

By year

Filings and what they reported, newest year first.

YearFilingsIncomeExpenses
20264$220K
20258$440K
20248$400K
20238$400K

Issues

The LDA issue codes the filings were filed under.

CodeIssueFilings
HCRHealth Issues28
MMMMedicare/Medicaid28
TRDTrade (domestic/foreign)18
BUDBudget/Appropriations14
CPTCopyright/Patent/Trademark14
TAXTaxation/Internal Revenue Code14
TARTariff (miscellaneous tariff bills)1

Bills

The bills the filings name, by how many name them.

BillTitleFilings
H.R. 1672Maintaining Investments in New Innovation Act11
S. 832EPIC Act of 20259
H.R. 5376Impacts and Outcomes for Health Career Training Act6
H.R. 5539POW Priority Care Act of 20255
S. 3131USS Frank E. Evans Act5
H.R. 1492To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…4
H.R. 3037Access to Breast Cancer Diagnosis Act of 20252
S. 1500Access to Breast Cancer Diagnosis Act of 20252
H.R. 5547To amend the Elementary and Secondary Education Act of 1965 to provide for additional activities, resources,…1
H.R. 946ORPHAN Cures Act1
S. 476White Oak Resiliency Act of 20251

Lobbyists

Named on the filings.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, newest first.

ClientRegistrantPeriodReportedPosted
NOVARTIS, INC.FORBES-TATE2026 second_quarter$50KJul 20, 2026
NOVARTIS, INC.TODD STRATEGY GROUP2026 second_quarter$60KJul 17, 2026
NOVARTIS, INC.TODD STRATEGY GROUP2026 first_quarter$60KApr 20, 2026
NOVARTIS, INC.FORBES-TATE2026 first_quarter$50KApr 18, 2026
NOVARTIS, INC.TODD STRATEGY GROUP2025 fourth_quarter$60KJan 21, 2026
NOVARTIS, INC.FORBES-TATE2025 fourth_quarter$50KJan 18, 2026
NOVARTIS, INC.TODD STRATEGY GROUP2025 third_quarter$60KOct 21, 2025
NOVARTIS, INC.FORBES-TATE2025 third_quarter$50KOct 18, 2025
NOVARTIS, INC.TODD STRATEGY GROUP2025 second_quarter$60KJul 20, 2025
NOVARTIS, INC.FORBES-TATE2025 second_quarter$50KJul 17, 2025
NOVARTIS, INC.TODD STRATEGY GROUP2025 first_quarter$60KApr 21, 2025
NOVARTIS, INC.FORBES-TATE2025 first_quarter$50KApr 15, 2025
NOVARTIS, INC.TODD STRATEGY GROUP2024 fourth_quarter$50KJan 22, 2025
NOVARTIS, INC.FORBES-TATE2024 fourth_quarter$50KJan 19, 2025
NOVARTIS, INC.TODD STRATEGY GROUP2024 third_quarter$50KOct 21, 2024
NOVARTIS, INC.FORBES-TATE2024 third_quarter$50KOct 18, 2024
NOVARTIS, INC.TODD STRATEGY GROUP2024 second_quarter$50KJul 19, 2024
NOVARTIS, INC.FORBES-TATE2024 second_quarter$50KJul 13, 2024
NOVARTIS, INC.TODD STRATEGY GROUP2024 first_quarter$50KApr 23, 2024
NOVARTIS, INC.FORBES-TATE2024 first_quarter$50KApr 15, 2024
NOVARTIS, INC.TODD STRATEGY GROUP2023 fourth_quarter$50KJan 19, 2024
NOVARTIS, INC.FORBES-TATE2023 fourth_quarter$50KJan 16, 2024
NOVARTIS, INC.TODD STRATEGY GROUP2023 third_quarter$50KOct 21, 2023
NOVARTIS, INC.FORBES-TATE2023 third_quarter$50KOct 17, 2023
NOVARTIS, INC.TODD STRATEGY GROUP2023 second_quarter$50KJul 20, 2023